LEO Pharma Submits Label Expansion Application to EMA for Anzupgo in Adolescent Chronic Hand Eczema Patients
Monday, December 15, 2025
LEO Pharma A/S, a leading global player in medical dermatology based in Ballerup, Denmark, has taken a significant step forward in addressing unmet needs in pediatric dermatology by submitting a label expansion application to the European Medicines Agency (EMA). Announced on December 15, 2025, this application seeks to extend the approval of Anzupgo® (delgocitinib) cream to adolescent patients aged 12 to 17 years suffering from moderate to severe chronic hand eczema (CHE) for whom topical corticosteroids are inadequate or inappropriate. The EMA has accepted the application for review, marking a crucial milestone in the company's strategy to broaden treatment access across the European Union.
Chronic hand eczema represents a debilitating condition that severely impacts quality of life, particularly in younger patients where current therapeutic options are limited. Adolescents in this age group currently lack specifically approved treatments for moderate to severe CHE in the EU, leaving a critical gap in care. Anzupgo, a topical Janus kinase (JAK) inhibitor, has already demonstrated efficacy in adults, and this expansion leverages robust clinical data to support its use in adolescents. Delgocitinib works by modulating inflammatory pathways, offering a non-steroidal alternative that could transform management of this chronic inflammatory skin disease.
The submission underscores LEO Pharma's commitment to innovation in dermatology, aligning with broader European regulatory efforts to expedite access to therapies for underserved populations. Sophie Lamle, Executive Vice President of Development at LEO Pharma, emphasized the company's dedication, stating, “With the submission of our label expansion application for Anzupgo®, LEO Pharma is reinforcing our commitment aiming at improving the lives of patients with skin diseases.” This move is part of LEO Pharma's global expertise in advancing dermatological treatments, potentially setting a precedent for future expansions in pediatric indications.
From a strategic perspective, this development bolsters LEO Pharma's position in the competitive EU dermatology market. The company, known for its focus on medical dermatology, continues to invest heavily in R&D to address chronic skin conditions. Chronic hand eczema affects a significant portion of the population, with adolescents facing unique challenges due to growth, lifestyle, and psychological factors. By targeting this demographic, LEO Pharma aims to capture a growing segment while contributing to public health initiatives that prioritize early intervention.
Regulatory experts anticipate a thorough review process by the EMA, given the conditional aspects often associated with expansions in novel therapies. The acceptance for review indicates that the dossier meets initial standards, including comprehensive safety and efficacy data from clinical trials involving adolescents. These trials likely demonstrated favorable risk-benefit profiles, comparable to adult data, with attention to long-term safety in younger patients. This aligns with EMA's emphasis on science-based evaluations to ensure patient safety.
In the broader context of EU pharmaceutical regulations, this submission occurs amid ongoing reforms aimed at streamlining approvals and enhancing access. LEO Pharma's proactive approach positions it well within these changes, potentially accelerating market entry. For industry partners, this signals opportunities in supply chain optimization and co-development for topical therapies. Manufacturing implications include scaling production to meet anticipated demand across EU member states, ensuring compliance with stringent GMP standards.
Looking ahead, approval could open doors for further indications and combinations, reinforcing Anzupgo's role in LEO Pharma's portfolio. The company's pipeline in dermatology remains robust, with investments in digital health tools for disease monitoring and personalized treatment plans. This label expansion not only addresses immediate clinical needs but also supports long-term strategies for chronic disease management in Europe.
Stakeholders in the biopharma sector will monitor the EMA's timeline closely, as positive outcomes could influence similar applications from competitors. LEO Pharma's focus on adolescent CHE exemplifies how targeted R&D can drive both patient outcomes and business growth, contributing to the EU's life sciences ecosystem. With global headquarters in Denmark, the firm leverages its European roots to navigate regulatory landscapes effectively, fostering collaborations that advance therapeutic innovation.
Ultimately, this development highlights the dynamic interplay between clinical research, regulatory strategy, and market expansion in the EU pharma landscape. As LEO Pharma awaits the EMA's decision, the potential impact on adolescent patients underscores the value of sustained investment in underserved areas of dermatology.
